What Lexicon Pharmaceuticals does

Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) is a publicly traded biopharmaceutical company headquartered in The Woodlands, Texas, founded in 1995. The company develops precision medicines for cardiometabolic diseases and chronic pain using a proprietary genomics-based target discovery platform built on Nobel Prize-winning technology. Its portfolio is anchored by INPEFA (sotagliflozin), the first and only dual SGLT1/2 inhibitor approved for heart failure in the United States, alongside investigational candidates including LX9851 (a first-in-class oral ACSL5 inhibitor for obesity), pilavapadin (a non-opioid candidate for diabetic peripheral neuropathic pain advancing to Phase 3), Zynquista (sotagliflozin for Type 1 diabetes with NDA resubmission planned in 2026), the SONATA-HCM Phase 3 program in hypertrophic cardiomyopathy, and LX9211 in chronic pain.

The company monetizes through a hybrid model: direct US commercialization of INPEFA ($4.6 million in net product revenue in FY2025; $1.1 million in Q1 2026), licensing royalties from Viatris for ex-US territories ($45 million in FY2025), and milestone payments plus royalty potential from the Novo Nordisk license for LX9851 (up to $1 billion in milestones plus tiered royalties, with a $20 million development milestone already recognized in Q1 2026). FY2025 total revenue was $49.8 million, up 60% year-over-year. Operating economics are improving with Q1 2026 net loss narrowing to $1.0 million from $25.3 million in the prior-year quarter.

Capital structure is built on substantial dilutive and debt financing executed across 2022–2026, including an $85 million public offering (2022), a $150 million Oxford Finance loan facility (2022), a $250 million private placement led by Invus, Braidwell, Great Point Partners, and OrbiMed (March 2024), a $94.6 million public offering and concurrent private placement (February 2026), and a $100 million Hercules Capital loan facility (May 2026). The customer base consists of end-patients in cardiology, endocrinology and pain management, but revenue is functionally dependent on two anchor pharmaceutical partners (Viatris and Novo Nordisk), creating high partner concentration.

Name

Lexicon Pharmaceuticals

Legal name

Lexicon Pharmaceuticals, Inc.

Website

https://lexpharma.com

Company type

Public

Founded year

1995

Operating status

Operating

Headcount range

101–250 employees

Short description

Lexicon Pharmaceuticals (NASDAQ: LXRX) is a biopharmaceutical company developing precision medicines for cardiometabolic disease and chronic pain via its genomics-based target discovery platform, commercializing INPEFA for heart failure while advancing pipeline candidates in obesity and neuropathic pain.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals - Cardiometabolic and Chronic Pain Therapeutics

NAICS

Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Translational Medicine & Biomarkers (HLAIALAF)

akta.pro secondary industry

Pain Management & Anesthesiology Pharmaceuticals (HLAIAAAN)

Keywords

• Cardiometabolic therapeutics
• Small molecule drugs
• Heart failure treatment
• Neuropathic pain drugs
• Genomics drug discovery

Headquarters

HQ city

The Woodlands

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

1. Product Sales (INPEFA): Direct sales of INPEFA (sotagliflozin) in the US market. Q1 2026 net sales were $1.1 million compared to minimal revenue in Q1 2025. FY2025 net product revenue was $4.6 million.
2. Licensing and Milestone Payments (Novo Nordisk): Lexicon entered an exclusive worldwide license agreement with Novo Nordisk for LX9851 in March 2025. The partnership provides milestone payments including $10 million for Phase 1 initiation, with up to $1 billion in total potential payments plus tiered royalties on net sales. Q1 2026 revenue included $20 million development milestone payment from Novo Nordisk.
3. Licensing Revenue (Viatris): Viatris holds exclusive licensing rights for sotagliflozin commercialization outside US and Europe. Licensing revenue reached $45 million in FY2025 from this partnership.
4. Debt Financing: Lexicon secured $150 million loan facility with Oxford Finance in 2022 for sotagliflozin commercialization, and $100 million loan facility with Hercules Capital in 2026 with $55 million received at closing.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

Lexicon Pharmaceuticals is a biopharmaceutical company that discovers and develops precise medicines for human disease using its genomics target discovery platform based on Nobel Prize-winning technology. Its commercial product INPEFA (sotagliflozin) is a dual SGLT1/2 inhibitor approved for heart failure, and the company is advancing a pipeline that includes Zynquista for type 1 diabetes, LX9851 for obesity, and Pilavapadin for diabetic peripheral neuropathic pain.

Product overview

Lexicon Pharmaceuticals is a biopharmaceutical company pioneering medicines using gene science for cardiometabolic diseases and chronic pain. The company operates a portfolio of commercial and investigational products: Inpefa (sotagliflozin) is the commercially available dual SGLT1/2 inhibitor for heart failure marketed by partner Viatris; Zynquista is the same molecule under NDA resubmission for Type 1 diabetes; LX9851 is an ACSL5 inhibitor for obesity licensed to Novo Nordisk in Phase 1; pilavapadin is advancing to Phase 3 for diabetic peripheral neuropathic pain; and the SONATA-HCM program is evaluating sotagliflozin in hypertrophic cardiomyopathy. The company leverages its genomics target discovery platform to develop targeted therapies across these therapeutic areas.

Differentiator

Problem solved

Functional benefit

Brands

• INPEFA: Brand name for sotagliflozin, a dual SGLT1/2 inhibitor approved for the treatment of heart failure.
• Zynquista

Products and services

• INPEFA (sotagliflozin) Dual SGLT1/2 inhibitor approved for the treatment of heart failure. First and only dual SGLT1/2 inhibitor approved for heart failure indication, demonstrating a 33% reduction in composite risk of heart failure hospitalization, urgent visits, and cardiovascular death versus placebo in Phase 3 trials. Commercialized by Lexicon directly in the US and by partner Viatris in certain international territories.
• LX9851 First-in-class oral non-incretin small molecule inhibitor targeting obesity and metabolic disorders by inhibiting Acyl CoA Synthetase 5 (ACSL5), a key regulator of fat accumulation and energy balance. Licensed exclusively to Novo Nordisk for worldwide development and commercialization.
• Pilavapadin Drug candidate for diabetic peripheral neuropathic pain (DPNP). PROGRESS Phase 2b study demonstrated that the 10 mg dose achieved nominally significant reduction in Average Pain at Week 8 versus placebo with good tolerability. Potentially the first non-opioid treatment for this condition in over two decades.
• Zynquista (sotagliflozin) Sotagliflozin being developed as an insulin adjunct for Type 1 diabetes. Same molecule as INPEFA but different brand and indication; NDA resubmission planned for 2026 based on STENO1 trial data.
• LX9211 Drug candidate in development for chronic pain indications, part of Lexicon's pipeline focusing on neuropathic and chronic pain therapeutics.

Quantifiable outcome

• 33% reduction in composite risk of heart failure hospitalization, urgent visits, and cardiovascular death vs placebo
• +3 more outcomes

Named customers3 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered minor and core.

• JefferiesminorGTM or Marketing Partner · 1 March 2026Lexicon presented at the Leerink Global Healthcare Conference 2026 and participates in Jefferies healthcare conferences as part of investor relations and strategic communication activities.
• Novo NordiskcoreStrategic or Co-development Partner · 1 March 2025Exclusive worldwide license agreement for LX9851, a first-in-class oral obesity drug candidate targeting ACSL5. Lexicon received $10 million milestone payment for Phase 1 initiation in March 2026, with eligibility for up to $1 billion in total milestone payments plus tiered royalties on net sales. The Phase 1 study is evaluating safety and pharmacokinetics in 96 participants with overweight or obesity, expected to complete Q1 2027.
• ViatriscoreChannel Partner/ Reseller/ DistributorExclusive licensing agreement for sotagliflozin commercialization outside US and Europe. Viatris launched Inpefa in the United Arab Emirates in early 2026, marking the first country in Viatris territories. Regulatory filings submitted in Canada, Australia, and Mexico. Viatris provides licensing revenue of $45 million in FY2025.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Madrigal Pharmaceuticals: Single-product cardiometabolic biotech with FDA-approved Rezdiffra (resmetirom) for MASH. Closely comparable to Lexicon in commercial stage, revenue scale, and focus on a single therapeutic area (cardiometabolic disease), with similar trajectory from milestone-driven to product-driven revenue.
• Viking Therapeutics: Clinical-stage biotech developing obesity therapeutics (oral and injectable candidates including a GLP-1/GIP dual agonist). Direct competitor to LX9851 for the obesity opportunity and comparable small-mid-cap public biotech with cardiometabolic focus.
• Cytokinetics: Cardiovascular specialty pharma with cardiac myosin modulator (Aficamten) for HCM. Directly comparable to Lexicon's heart failure / cardiometabolic therapeutic focus, similar small-mid-cap public biotech profile, and reliance on licensing partnerships alongside direct commercialization.
• Tenax Therapeutics: Small-cap cardiovascular specialty biotech developing drugs for pulmonary and cardiac indications (notably LEVO-CTS for low cardiac output syndrome). Comparable size and therapeutic-area focus (heart failure) to Lexicon, with similar clinical-stage asset structure.
• Crinetics Pharmaceuticals: Small-mid-cap specialty pharma with first-in-class discovery platform for endocrine/metabolic diseases. Comparable business model (gene-driven drug discovery → clinical development) and scale to Lexicon, with similar single-platform focus translating innovation into clinical assets.
• Travere Therapeutics: Small-mid-cap specialty biopharmaceutical with commercial products and late-stage rare-disease pipeline. Comparable business model (licensed/in-licensed product portfolio + clinical pipeline) and similar revenue scale to Lexicon, with analogous mix of milestone revenue and modest direct sales.
• Harmony Biosciences: Specialty biopharmaceutical with CNS focus (commercial Wakix) and in-licensed/pipeline assets. Comparable small-mid-cap profile with single-product revenue base, similar reliance on specialty channel commercialization and partnership-driven pipeline growth.

Emerging players

• Structure Therapeutics: Clinical-stage biotech developing oral GLP-1 small molecules for obesity and metabolic disease. Emerging competitor to Lexicon's LX9851 in obesity with a complementary oral, non-injectable mechanism angle; similar small-mid-cap profile with cardiometabolic focus.

Broad incumbents

• AstraZeneca: Large pharma whose Farxiga (dapagliflozin) is the leading SGLT2 inhibitor for heart failure and CKD. Directly competes with Lexicon's INPEFA/sotagliflozin in heart failure prescribing decisions; broader incumbent across multiple therapeutic areas including cardiology and rare disease.
• Eli Lilly: Mega-cap pharma with Jardiance (empagliflozin SGLT2 co-promoted with Boehringer Ingelheim for HF) and Zepbound (tirzepatide for obesity). Direct SGLT2 heart failure competitor to INPEFA and dominant obesity competitor to LX9851, with vastly greater commercialization resources.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/LexPharma
• Facebookfacebook.com/Lexicon-Pharmaceuticals-Inc-1658524937805248
• LinkedInlinkedin.com/company/lexicon-pharmaceuticals

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds13 records

Investors17 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lexicon Pharmaceuticals